PanTher Therapeutics Awarded $14.2M from CPRIT to Advance Targeted, Localized and Sustained Cancer Treatment
PanTher Therapeutics (PanTher or the Company), a clinical-stage oncology company developing next-generation targeted therapies for solid tumors, received a $14.2 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).
- PanTher Therapeutics (PanTher or the Company), a clinical-stage oncology company developing next-generation targeted therapies for solid tumors, received a $14.2 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).
- The Sagittari platform leverages interventional oncology procedures to design superior localized cancer treatments with adaptability to multiple solid tumor indications.
- The CPRIT also awarded nine prevention grants focused on increasing cancer-prevention and three recruitment grants aimed at enhancing cancer research efforts across Texas.
- PanTher Therapeutics (PanTher) is a clinical-stage oncology company revolutionizing cancer care by harnessing sustained treatments engineered for localized applications.